BO LIM: Open Payments
NPI 1861193328 · KIRKLAND, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,222 in 54 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $60 · 2025 $1,222
Food & beverage: $1,222
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $227 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $170 |
| Madrigal Pharmaceuticals | 5 | $129 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $116 |
| Ipsen Biopharmaceuticals, Inc | 4 | $111 |
| GENZYME CORPORATION | 4 | $96 |
| Janssen Biotech, Inc. | 3 | $79 |
| Regeneron Healthcare Solutions, Inc. | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 4 | $67 |
| Lilly USA, LLC | 2 | $57 |
Products named: ENTYVIO, DUPIXENT, REZDIFFRA, XIFAXAN, RINVOQ, IQIRVO, TREMFYA, SKYRIZI.
Industry payments across WA — which companies pay providers there.
